Vascular Targeting Viral Therapy Augments Pd-L1 Checkpoint Blockade Anti-Tumor Activity

被引：0
|
作者：
Breitbart, Eyal [1 ]
Mendel, Itzhak [1 ]
Yacov, Niva [1 ]
机构：
[1] VBL Therapeut, Or Yehuda, Israel
来源：
MOLECULAR THERAPY | 2017年 / 25卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
585
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [21] Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
    Tan, Shuguang
    Zhang, Catherine W-H
    Gao, George F.
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2016, 1
  • [22] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
    Song, Yue
    Li, Zhaoming
    Xue, Weili
    Zhang, Mingzhi
    IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
  • [23] Combination of PD-1/PD-L1 checkpoint blockade and dendritic cell therapy
    Nesselhut, J.
    Marx, D.
    Lange, H.
    Chang, R. Y.
    Nesselhut, T.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 48 : 95 - 95
  • [24] Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
    Shuguang Tan
    Catherine W-H Zhang
    George F Gao
    Signal Transduction and Targeted Therapy, 1
  • [25] Targeting the intrinsic signaling of PD-L1 in human monocytes by a novel PD-L1 antibody to promote anti-tumor immunity.
    Hsu, Michelle A.
    Liu, Xin
    Barham, Whitney
    Hirdler, Jacob
    Mao, Zhiming
    Lucien, Fabrice
    Dong, Haidong
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [26] A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
    Rubio-Perez, Laura
    Lazaro-Gorines, Rodrigo
    Harwood, Seandean L.
    Compte, Marta
    Navarro, Rocio
    Tapia-Galisteo, Antonio
    Bonet, Jaume
    Blanco, Belen
    Lykkemark, Simon
    Ramirez-Fernandez, Angel
    Ferreras-Gutierrez, Mariola
    Dominguez-Alonso, Carmen
    Diez-Alonso, Laura
    Segura-Tudela, Alejandro
    Hangiu, Oana
    Erce-Llamazares, Ainhoa
    Blanco, Francisco J.
    Santos, Cruz
    Rodriguez-Peralto, Jose L.
    Sanz, Laura
    Alvarez-Vallina, Luis
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [27] Reversing tumor immunosuppressive microenvironment via targeting codelivery of CpG ODNs/PD-L1 peptide antagonists to enhance the immune checkpoint blockade-based anti-tumor effect
    Zhang, Min
    Fang, Zhou
    Zhang, Haitao
    Cui, Mingxiao
    Wang, Mingfu
    Liu, Kehai
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 168
  • [28] A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
    Cui, Xiaopei
    Jia, Huifeng
    Xin, Hong
    Zhang, Lei
    Chen, Shi
    Xia, Simin
    Li, Xue
    Xu, Wei
    Chen, Xiaofang
    Feng, Yujie
    Wei, Xiaoyue
    Yu, Haijia
    Wang, Yanting
    Zhan, Yifan
    Zhu, Xiangyang
    Zhang, Xuemei
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [29] Targeting Glutamine Metabolism and PD-L1: A Novel Anti-tumor Pas de Deux
    Matias, Maria I.
    Dardalhon, Valerie
    Taylor, Naomi
    MOLECULAR CELL, 2020, 80 (04) : 555 - 557
  • [30] PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma
    Park, Jeong A.
    Guo, Hong Fen
    Xu, Hong
    Cheung, Nai-Kong V.
    BLOOD, 2019, 134
12345